HIGHLIGHTS
- who: Ryoichi Miyazaki from the (UNIVERSITY) have published the article: Empagliflozin in kidney transplant recipients with chronic kidney disease G3a-4 and metabolic syndrome: five Japanese cases, in the Journal: (JOURNAL)
- future: Studies will be required to clarify the efficacy and safety of SGLT2 inhibitors in a larger group of patients with similar medical conditions.
SUMMARY
As mortality during an 8-year follow-up period after kidney transplantation was reportedly 16% among nondiabetic patients but 22% among diabetic patients. Dipeptidyl peptidase-4 (DPP-4) inhibitors, which can be used relatively safely . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.